Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Analyse van circulerend tumor-DNA bij patiënten met ‘ALK’-positieve longkanker
dec 2019 | Longoncologie